Drug Profile
TCS gene delivery systems - Inex Pharmaceuticals/Protiva Biotherapeutics
Latest Information Update: 17 Jun 2002
Price :
$50
*
At a glance
- Originator Inex Pharmaceuticals Corporation; Protiva Biotherapeutics
- Class Small interfering RNA
- Mechanism of Action Immunostimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jun 2002 Discontinued - Preclinical for Cancer in Canada (Parenteral)
- 05 Nov 1997 Preclinical development for Cancer in Canada (Parenteral)